In Salt Lake City on September 18, 2025, Co-Diagnostics, Inc. (Nasdaq: CODX), a company specializing in molecular diagnostics, revealed the completion of its earlier disclosed transaction. The Company's patented platform for molecular diagnostic tests sets it apart in the industry.